

Nicholas Hall Writes:

The global CHC industry is at a crossroads, facing uncertainty over market direction and performance, while the speed of change continues to accelerate at pace. With brand owners facing new strategic challenges and needing to identify innovative approaches to stay ahead of the game, my all-new signature report is very timely.


Providing a new Strategic Narrative for CHC, this report acts as the ultimate blueprint for all CHC stakeholders in how to exploit business opportunities and manage threats today and in the future.



hands tan

NEW PARADIGMS FOR CHC 2023

A CHC STRATEGIC NARRATIVE FOR THE NEW YEAR



- 2 Simplicity: Bring back simple propositions! End "disruption" as a marketing strategy – it only confuses consumers. Remember, confused consumers don't buy!
- 3 Credibility: Who does the consumer trust or believe? This is vital if we're going to defend brands against generics and private labels! "Trusted science" has a key role, but make sure clinical work can stand up to scrutiny!



Value: What does value mean to consumers? What is the relationship between price and benefits? The consumer is thinking about this all the

time, why aren't we? Some consumers are telling us they can't afford to Eat and Heat and Treat. Are we listening?

5 Degradation of Quality: We and

others cut corners to reduce costs, everything from flimsy Amazon packaging (result – our products arrive damaged) to reduced inventory (frequent retail out-of-stocks). Be sure, the consumer notices!

- 6 Adjacent Categories: Is this where we will find new sources of growth? I think so!
- **7 Rx-to-OTC Switch**: Back again, big time, using the new ACNU scheme in USA.



Shrink the Portfolio:

Our brands are too complex with too much segmentation and too many SKUs. Look at your brand portfolio from outside-in. Does every SKU deserve a place on-shelf? If not, delete. If you don't, the trade will!

9 A Year of M&A: Changing the shape of the CHC industry and possibly its dynamics.



Let's Say Goodbye to SPOs:

Sales Prevention Officers are everywhere – regulators,

retailers, consumer associations and the Dr No's at the European Food Safety Authority, who won't let us describe a probiotic as a probiotic on packaging. Worst of all are the SPOs inside our own companies. If we aim to be more nimble and entrepreneurial, we have to change the "we tried that before and it didn't work" mentality!

REPORT COVERAGE

THE FUTURE RESUMED



1. So What's the Big Idea?

- The global CHC market
- 10 Steps to Heaven
- 1. CBD, a long-distance race!
- 2. Mental Wellness: Problems highlighted by the pandemic
- 3. Sexual Health & Fertility
- 4. Women's Health, Ageing
- 5. Sustainability
- 6. Natural & Organic Products
- 7. Food Intolerance
- 8. E-commerce
- 9. AI
- 10. Emerging Markets
- The Big Ideas addressed in this report
- The 2024 Strategic Narrative

2. Covid & Its Aftermath

- How Covid-19 accelerated the shift to Self-Care
- Historical impact of recession on Consumer Healthcare
- The shifting landscape of consumer behaviour
- Growth categories during the pandemic
- Rethinking supply chains: how the pandemic exposed vulnerabilities

3. Classic Categories

- Analgesics: Few major opportunities so marketers filling in gaps
- Cough, Cold & Allergy: Heavily dependent on seasonal illness trends
- Gastrointestinals: New consumer benefits drive expansion
- Vitamins, Minerals & Supplements: Trusted science key to growth
- Dermatologicals: Resistant to growth
- Lifestyle CHC: A full spectrum of herbals to Rx-to-OTC switches

4. How to Innovate

- Why does the ratio of high-quality (3 and 4 star) innovations remain persistently low?
- Future microbiome and probiotics innovation will be driven by investment in clinical research
- Improved diagnostics will support VMS innovation and Rx-to-OTC switch
- Demand for diabetes prevention and management is giving fuel to supplement and diagnostic innovation
- Quality science and consumer trust key to successful weight loss innovation
- Demand for products promoting mental health and sleep growing post-pandemic




- Ageing demographic underpins supplement and plant-based protein innovation
- Focus on analgesics: New formats, switch and ingredient combinations drive innovation
- Focus on CCA: Natural-based formulations and allergy switches power NPD activity
- Focus on dermatologicals: Sustainable packaging and cutting-edge apps fuel NPD
- Focus on GIs / probiotics: Hangover cures, prebiotics and switch are key
- What does the future hold? Evolving NPD trends, personalisation, emerging niches

5. Rx-to-OTC Switch

- Rx-to-OTC switch in the healthcare ecosystem
- Why Switch? The uptake in telehealth & telemedicine
- Switch in Europe
- Can Switch be successful only in the USA?
- Voltaren Arthritis Pain: USA Switch journey
- US FDA's Additional Condition for Nonprescription Use (ACNU)
- Innovation hot spots in Switch Switch case studies
- On the horizon?

6. Demographic Timebomb

- A rapidly Growing Middle Class in *expanding* urban areas
- Generation cohorts: different attitudes & behaviours to health
- What is Middle Class?
- The three most important demographic groups
- What about men?
- Is there a Gender Gap?



7. Women's Healthcare: Listening to the Female Voice

- Women vs men Women's leading CHC role
- Menstrual pain and PMS
- Are the OTC contraception floodgates about to open?
- Menopause are there new growth opportunities?
- Overactive bladder OTC growth category or destined for failure?
- New thinking on endometriosis
- Women's brands and companies



REPORT COVERAGE

THE FUTURE RESUMED



8. Health Through Digestion

- The importance of the gut microbiome
- Mental health is a growth segment for probiotics
- Custom probiotics have the potential to disrupt
- The "biotics" family The "Gut-Muscle Axis": a new dimension for probiotics?
- Food allergies: the focus of much research
- Food intolerance
- Unhealthy lifestyles are driving demand for digestive remedies and other GIs
- Hangover cures form a new segment
- ORTs repositioning as lifestyle products

9. Mental Wellness

- Mental health problems soared during Covid-19, while economic worries are a continuing contributor to stress
- Spending on mental health & wellbeing remains a priority for consumers
- WHO declares a sleep pandemic
- Sleep quality is a top health priority for consumers



 ZzzQuil: Highly successful sleep aid, with 3 key development stages • Is the sales boost in sedatives & sleep aids sustainable? • New indications and ingredients in mental wellness • CBD for sleep & anxiety?

10. Cannabis

- A note on defining the market North America
- Europe Asia-Pacific

11. Sexual Health & Fertility

- Huge potential for daily OCs worldwide
- Education is central to expanding the reach of EHC
- Is a male contraceptive pill viable and is there demand?
- Condoms: Little NPD potential, so other ways to swell sales needed
 Menstrual pain / PMS market expands via launch activity



- Intimate care shows plenty of scope for expansion
- Menopause: UK sees the first over-the-counter HRT, while a new Rx drug may revolutionise treatment
- How big can the OTC ED market become?
- Do topicals represent a viable ED alternative?
- Can premature ejaculation treatments find a wider audience?
- Prenatal vitamins prove fertile ground for NPD

12. Obesity & Related Conditions

- Obesity is a huge determinant of health and the data is frightening
 Obesity crisis represents huge opportunity for CHC
 Where are the opportunities?
- Evidence-backed brands can be lost among the plethora of weight loss supplements & meal replacements
- Supporting consumers on their weight loss journey
- Apps & wearables for weight loss Semaglutide: Is the excitement justified? Obesity's link to other health conditions brings possibilities

13. Digital Revolution

- AI and chatbots Accessibility of data
- Medtech & wearables Apps
- Telehealth Digital communication

14. Sustainability

- Frameworks become regulations
- The Triple Bottom Line: People, Planet, Profit
- Environmental, Social & Governance (ESG) Reporting
- Collaborate to make progress Innovation, packaging & recycling drafting a roadmap to a circular economy
- Engineering, beauty & performance with environmental credentials Communicating sustainability
- Being in the Wellbeing Business



15. Emerging Markets

- Emerging Markets: attractive markets with some degree of uncertainty Emerging Markets forecasts
- Emerging Markets: What's holding back growth?
- CHC performance in selected Emerging Markets
- Nicholas Hall's 20 ways to succeed in the Emerging Markets





REPORT COVERAGE

THE FUTURE RESUMED



16. China

- China plans an economic reset
- Should I stay, or should I go?
- Lockdown easing brings a more positive outlook for CHC
- Despite a weakened economy, China's CHC market rebounded well • Population imbalance: the issues & opportunities of an ageing population
- Gen X goes green and young women lead online shopping trends
- "Sang culture" and "Me mentality" prevalent as consumers focus on health & wellness
- Covid-19 changes consumer preferences from overseas supplements to TCM
- China's fragmented pharma market starting to consolidate
- The NMPA seeks to incentivise innovation
- Technological advances: AI and R&D
- How to get ahead online
- Competition for e-commerce giants amid regulatory clampdown
- CHC product trends & opportunities
- Summary: What does all this mean for CHC players in China?

17. Distribution

- Overview
 Retail Category Management
- Pharmacy Point-of-Care In-store clinic model
- Leading pharmacy chains Private label
- General Sales List and self-selection
- Mass market E-commerce
- Thorne: Digitally-native personalised supplement brand with diagnostics presence
- Subscription model Shopper insights
- Patient / consumer journey

18. Competition

- Cluster Analysis 1: MNCs + True Pharma
- Cluster Analysis 2: MNCs + FMCG
- Cluster Analysis 3: Regional Players + True Pharma
- Cluster Analysis 4: Regional Players + FMCG

19. M&A So, What's the High Bear2 DHC comparison are imming more and more to MAA, and pict as a varie of a theoring scale to using immore group public, categories, prouge. A cognition or and elever them (cital abortcas and an experiment summing corner. It have every unpredictable, provide this categories and, although many acquisitions accessed commerciality, some on each, the great works for the summary acquisitions accessed commerciality, some end with the methods for comparent to iterate the sum is market.								User care localizesa, Robit Is the prime sample of an FMCG company for which even by programmers and the same sample of the SMCG company for which even by programmers and the same same same same same same same how a follow programmers and the same same same same same same programmers and the same same same same same same same sam											
venents	for conser	iners, out i	siely Bio	ws the ma	Met.				M&A share by sector (deal value)										
AL Consumer relationate purpers view for growing or saves and prostability, equivation is that a more entities transpire than standing mere products in a market that is conservative from the consumer and regulatory points of view. This trend is likely to continue as comparison study to a subvolum in a high-fragmented and changing, market contribut to precovery from the Covid-19 pandemic. Interview of the construction of the covid-19 pandemic.									53.968 2275 12.85 11.85 8.75 8.75	53,853 50,754 50,754 50,754 70,754 70,754	54.433 75% 12.2% 11.2%	16.95 16.95 16.25	S3,510 EGGN HLBN KLBN	55,605 1995 1995 1105	54,545 22,75 23,09 10,75	51,000 1925 1925 1925 1926 1926	•Maska A Anaxos ut •Mathaw		
spinning of	f (Haleon, H	Germue, Sar	nofi), we ar	e seeing th	e reverse t	rend as FN	ICG					215	110	7.85	105	10	1.7%	14.05	Soviet
companies such as Nestlé, Unilever and Church & Dwight boost growth by acquiring							20.5%	21.7%	21.05		1.0	1745	17.4%		10.00		 Groups 		
health & wellness companies, often with higher operating margins than achieved by CHC acquisitions by FMCG companies								mis	943N	22.0%	27.9%	a. 15	93N	34.8%	27.0%	an	**	•620 •128	
Bayer	2917	2018	2019	2020	2021	2922	2023		200	2015	2016	(107	206	52	500	ine.	2005	2002	•13
					_	_			Source	Pitchbox	a .							"June 30	3023
0					arean arean	E45 Sollo Keo			Healthca	re deal	flow by	year (C			Hea			evenue ca & Eur	multiples ope)
Nesse		arfailt n			inuun)	阙 20012】			BAX SIN BAX BAX			\bigwedge	140	L000 L000 L000 L000 L000				ŕ	Vi
ų			OLLY		welly	ENTRATOR			548 208 2.00 888 578	Ĩ			A .		Ĩ	1	ľ		Ĩ
₽&G			C		(ABM/CK)		P ****		****	11	///	9 <i>4 4</i>	1		04 (D4	-		300 MM	ource Pitchbook
And the second second second			277				15	NGLINA (MA	I FOR OH	C 2623			275				×	ICHOIAS Hall'S	

19. M&A

- Why M&A? Type of M&A models
- High acquisition multiples
- Ten Golden Rules of M&A

20. Managing Brands for Long-Term Growth

- Building trust in a brand beyond its science
- Managing price increases
- Tactics that could drive brand share in a static market
- How to compete in an industry dominated by generics
- How to leverage the New Paradigm WOW! Brands case studies: Innovation & scale
- Olly: Dynamic US brand, with supplements portfolio targeting female Millennials
- Lumify: Rx-to-OTC Switch eye care brand with heavy focus on cosmetic red eye benefits, backed by professional recommendation

10 STEPS TO HEAVEN

- 1. CBD A long distance race!
- 2. Mental Wellness: Problems highlighted by the pandemic
- 3. Sexual Health & Fertility
- 4. Women's Health, Ageing
- 5. Sustainability
- 6. Natural & Organic Products
- 7. Food Intolerance
- 8. E-commerce
- 9. AI
- 10. Emerging Markets

NICHOLAS HALL'S NEW PARADIGMS 2023 The Future Resumed

Order Form for New Paradigms 2023

A global licence will be required if you wish to put this report on your company's intranet. The report will be sent in PDF format to the purchaser via a secure link. If a print copy is required, please request this upon purchase. All prices are quoted in British Pound Sterling.

Pricing:

Please tick as appropriate. I would like to order:

Global Licence	GB£20,000
Site Licence	GB£16,000

Report purchases include access to a webinar of key findings presented by Nicholas Hall personally.

* Individual chapters can be purchased, please contact us to discuss your customised quotation.

Additional Pricing:

Additional customised presentation via webinar / in-house workshop conducted by Nicholas Hall GB£10,000+ (price dependent upon customisation and exact specification)

Additional customisation with 3 quarterly updates and presentation / discussion for the first year after publication (price dependent upon customisation and exact specification)

DELIVERY DETAILS			
Mr/Mrs/Ms/Dr/Other	_ First Name	Last Name	Job Title
Company	Address		
		_ Post/zip code	Country
Tel	Fax		Email

PAYMENT DETAILS

Please invoice my company quoting order number / reference:

(material will be sent when full payment is received)

VAT ID Number (EU only):

Signed:_____

Date: DD / MM / YYYY

GB£10,000+

If you do not wish to receive future information from us, please tick as appropriate:

Email

Please email the completed order form to info@NicholasHall.com



Nicholas Hall Group of Companies offers the world's most complete consumer healthcare marketing & business solutions

Dedicated to benchmarking consumer healthcare markets and providing business solutions, we are specialists in consumer healthcare, with an international network of contacts, offering data & analysis, strategic advice and competitive intelligence on a global, regional or local basis.



Latest Nicholas Hall Reports:

Nicholas Hall Europe Ltd, 35 Alexandra Street, Southend-on-Sea, SS1 1BW, UK E: info@NicholasHall.com W: www.NicholasHall.com T: +44(0)1702 220 200

